Orforglipron for adults who are overweight and at risk of obesity-related health problems
Tests orforglipron against placebo in adults who are overweight.
Plain-language title generated from the registry record
Registry title: A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Key facts
- Where
- A coruña, Alcobendas, Barcelona, Centelles, Chiclana De La Frontera, Granada, Madrid, Sevilla, and Valencia, SpainSee the 13 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with overweight who have an early warning sign such as prediabetes or prehypertension and have not lost weight with diet and exercise.
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Overweight with a BMI from 25 to 29.9 kg/m2 (or the equivalent regional overweight threshold) and a waist-to-height ratio of 0.5 or more. At least one early sign: prediabetes, prehypertension or predyslipidemia.
- Earlier treatment
- At least one unsuccessful attempt to lose weight with diet and exercise. No weight-loss medicines, including over-the-counter ones or alternative therapies, in the 180 days before screening. No past or planned obesity surgery or procedure.
Main reasons for not taking part
- Any type of diabetes
- Obesity diagnosis, or a past BMI of 30 kg/m2 or more
- Hypertension or a history of hypertension
- Dyslipidemia or a history of dyslipidemia
- Body weight not stable in the 90 days before screening
Read by machine on 11 November 2026.
Where in Spain
- C.R.A. Investigación ClínicaA coruña, SpainTaking people
- Accellacare Espana S.L.Alcobendas, SpainTaking people
- Equip D'atencio Primaria Barcelona Sardenya S.L.P.Barcelona, SpainTaking people
- FutureMeds BarcelonaBarcelona, SpainTaking people
- Hospital Universitari Vall d'HebronBarcelona, SpainTaking people
- EAP Osona Sud - Alt Congost S.L.PCentelles, SpainTaking people
- Futuremeds Spain S.L.Chiclana De La Frontera, SpainTaking people
- Hospital Vithas La SaludGranada, SpainTaking people
- Centro de Salud San Juan de la CruzMadrid, SpainTaking people
- Futuremeds Spain S.L.Madrid, SpainTaking people
- Futuremeds Spain S.L.Sevilla, SpainTaking people
- Vithas Hospital SevillaSevilla, SpainTaking people
- Hospital AsciresValencia, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07794579EU 2026-526175-35-00
- Record updated
- 5 November 2026
- Original description
This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and dyslipidemia, and progression to class 1 obesity.Read full original descriptionShow less
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Individuals With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and dyslipidemia, and progression to class 1 obesity.
Inclusion: Have an increased waist-to-height ratio of ≥0.5; Have at least one pre-obesity-related complication (prediabetes, prehypertension, predyslipidemia); Have at least one unsuccessful attempt to reduce body weight based on diet and exercise; Have a BMI greater than or equal to 25 to less than or equal to 29.9 kg/m2 or equivalent-/region-specific overweight thresholds.
Exclusion: Do not have a stable body weight within 90 days before screening; Have taken medications for weight loss, including over-the counter medications or alternative therapies, within 180 days prior to screening; Have a prior or planned surgical treatment or procedure for obesity; Have type 1 diabetes, type 2 diabetes, or any other type of diabetes; Have a documented obesity diagnosis or self-reported history of BMI ≥30 kg/m² (or an equivalent region-specific threshold); Have hypertension or history of hypertension; Have dyslipidemia or history of dyslipidemia.